Boston Scientific To Market Celsion’s Prolieve BPH Device Immediately
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will promote Celsion's Prolieve microwave urethroplasty system as a less-painful alternative to existing treatments for benign prostatic hyperplasia (BPH), following FDA approval Feb. 19
You may also be interested in...
Celsion sheds BPH microwave system
Boston Scientific picks up Celsion's Prolieve microwave urethroplasty system for $60 million, Celsion announces April 18. Boston Scientific will pay $30 million at the close of the deal and two annual installments of $15 million. Boston Scientific began selling the Prolieve benign prostate hyperplasia treatment system in 2004 under a distribution agreement that had been set to expire in 2009 (1"The Gray Sheet" Feb. 23, 2004, p. 23). The sale of Prolieve completes Celsion's transition to an oncology focused drug company...
Celsion sheds BPH microwave system
Boston Scientific picks up Celsion's Prolieve microwave urethroplasty system for $60 million, Celsion announces April 18. Boston Scientific will pay $30 million at the close of the deal and two annual installments of $15 million. Boston Scientific began selling the Prolieve benign prostate hyperplasia treatment system in 2004 under a distribution agreement that had been set to expire in 2009 (1"The Gray Sheet" Feb. 23, 2004, p. 23). The sale of Prolieve completes Celsion's transition to an oncology focused drug company...
TherMatrx Purchase Gives American Medical Systems In-Office BPH Presence
American Medical Systems expects the physician office market for benign prostate hyperplasia treatment to continue to grow by greater than 30% following its acquisition of in-office microwave BPH firm TherMatrx